Tizona to Present at The Cowen and Company 40th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today that Scott Clarke, Chief Executive Officer, will present at The Cowen and Company 40th Annual Healthcare Conference on Wednesday, March 4th at 2:00pm ET in Boston, MA.
The corporate presentation will be made available on the “news” section of the Tizona website at www.tizonatx.com.
About Tizona Therapeutics, Inc.
Tizona is a privately held, clinical-stage immunotherapy company that develops first-in-class medicines to deliver transformational benefits for people with cancer. Tizona translates scientific breakthroughs into therapeutics that stimulate the immune system and counter immune suppression. Tizona’s lead program, TTX-030, a first-in-class anti-CD39 antibody, is being developed in collaboration with AbbVie. It is currently being studied in a phase 1/1b clinical trial as a monotherapy and in combination with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer (NCT03884556).
Contact:
Investors:
Shari Annes, Annes Associates
sannes@annesassociates.com
650-888-0902
Media:
Janet Graesser
jgraesser@tizonatx.com
917-685-8799
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
